Drugs / AGEN1423
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05632328 | Aug 2024 → Aug 2026 overdue | pancreatic ductal adenocarcinoma | Bruno Bockorny | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06300463 | Mar 2024 → Dec 2026 expected | metastasis from malignant tumor of colon | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-03-13 | Agenus Inc. | Regulatory Agenus Milestone Triggers $7.5M Payment from Gilead agenusbio.com ↗
FDA has accepted IND filing for AGEN1423 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-03-13 | Agenus Inc. | Agenus Milestone Triggers $7.5M Payment from Gilead agenusbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGEN1423 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06300463 ↗ |
| Route | Intravenous | “via IV, dosage per protocol, once every 2 weeks for up to 8 weeks” NCT05632328 ↗ |